Trying for a BRAF Slam Dunk

Cancer Discov. 2020 May;10(5):640-642. doi: 10.1158/2159-8290.CD-20-0231.

Abstract

The first basket clinical trial testing the BRAF inhibitor vemurafenib resulted in evidence of activity in 13 unique cancer types with BRAF V600 mutations, but the response rates were variable. Therefore, different cancer histologies with the same driver oncogene display different degrees of oncogenic pathway addiction.See related article by Subbiah et al., p. 657.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Humans
  • Mutation
  • Neoplasms* / drug therapy
  • Neoplasms* / genetics
  • Protein Kinase Inhibitors / therapeutic use
  • Proto-Oncogene Proteins B-raf* / genetics
  • Vemurafenib

Substances

  • Protein Kinase Inhibitors
  • Vemurafenib
  • BRAF protein, human
  • Proto-Oncogene Proteins B-raf